Hope on the Horizon: Ocugen Completes Enrollment for OCU400 Phase 3 Trial
For individuals and families navigating the challenges of inherited retinal diseases (IRDs), news of advancements in gene therapy offers a beacon of hope. Ocugen, Inc. has announced a significant milestone: the completion of enrollment for its Phase 3 liMeliGhT clinical trial evaluating OCU400, a modifier gene therapy candidate for Retinitis Pigmentosa (RP). This development is particularly impactful for the IRD community as OCU400 is designed with a gene-agnostic approach, meaning it aims to treat multiple genetic mutations linked to RP, potentially offering a broader solution than many existing gene therapies.
OCU400 is based on a nuclear hormone receptor gene called NR2E3, which plays a crucial role in regulating various retinal functions, including photoreceptor development, maintenance, and cell survival. Instead of targeting a single mutated gene, OCU400 works by resetting dysfunctional retinal gene networks to restore a healthy balance within the cells. This approach is vital because RP is associated with mutations in over 100 genes, and current gene replacement therapies typically address only a small subset of these. This makes OCU400 a potentially groundbreaking treatment for the approximately 98% of RP patients who are not eligible for currently approved single-mutation gene therapies.
The Phase 3 liMeliGhT trial successfully enrolled 140 participants across various ages, including pediatric patients aged three years and older, and spans early to late stages of disease progression. Participants in the trial received a sub-retinal injection of OCU400. The primary endpoint for the study is the 12-month change in visual function, measured by a luminance dependent navigation assessment (LDNA), which is designed to detect clinically meaningful changes in mobility performance.
This completion of enrollment brings the IRD community closer to potential new treatment options. Topline data from the one-year study are anticipated in the first quarter of 2027. If successful, these results are expected to support a Biologics License Application (BLA) filing in 2027. Furthermore, the European Medicines Agency (EMA) has confirmed that the U.S.-based trial will be acceptable for a future Marketing Authorization Application (MAA), paving the way for potential availability in Europe as well. Ocugen plans to initiate a rolling BLA submission in the third quarter of 2026.
While the completion of enrollment is a significant step, the community now awaits the trial results with cautious optimism. This gene-agnostic approach could offer a new paradigm for treating a broad range of inherited retinal diseases, potentially transforming the lives of many affected individuals.